BRCA1 and ovarian cancer: Moreover, the BRCA1/2 mutation status of an ovarian cancer patient can be an important aspect in regards to the decision of chemotherapy; BRCA1/2 carriers show increased sensitivity to platinum-based therapy [6], [7], as well as to poly-ADP-ribose polymerase inhibitors [8].